As such, targeting ENO2 and its interactions with HIF-1α could potentially offer novel therapeutic avenues for ccRCC treatment by exploiting the vulnerabilities that arise from metabolic adaptations. The gene discussed is HIF1A; the disease is nonpapillary renal cell carcinoma.